Skip to main content

Table 9 Relation between study power and effectiveness

From: Oncologic orphan drugs approved in the EU – do clinical trial data correspond with real-world effectiveness?

 

Effectiveness

 

Survival benefit > 3 months

Survival benefit < 3 months, unknown magnitude or no benefit

Total

Study power

Adequately powered

6

2

8

Underpowered

0

2

2

 

Total

6

4

10

Back to article page

Orphanet Journal of Rare Diseases

ISSN: 1750-1172